Fig. 5
From: Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas
Effect of denosumab and trastuzumab in cell properties of breast cancer cells. a, b XTT proliferation assay for SKBR3 and BT-474 cells, after treatment with RANKL, denosumab, and/or trastuzumab for 24 and 72 h. Results are expressed in the histogram as growth inhibition, normalized to the control group. c, d Representative images of clonogenic assay performed at SKBR3 and BT-474 cells. e, f The histograms represent data from FACS analysis using annexin V-FITC and propidium iodide (PI) of SKBR3 and BT-474 cells after 48 h of treatment. The histograms show the distribution of cells as percentage of viable, apoptotic and necrotic. g, h Quantification of migration-wound healing assay for SKBR3 and BT-474 cells analyzed at 24 and 48 h. The histogram shows percent wound recovery at 24 and 48 h in relevance to 0 h. Data in a–h were analyzed by one-way ANOVA and represent mean ± SD. Asterisks indicate *p < 0.05, **p < 0.01, and ***p < 0.001